OVID News and Press, Ovid Therapeutics Inc. From 05/10/22

Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in the fourth quarter of 2022 Data supporting OV329 in rare and treatment-resistant epilepsies expected to be presented at the upcom...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbCellera Biologics ( ABCL ): Impressive sales growth is very promising for this firm and its antibody discovery platform. SIGA Technologies ( SIGA ): Improved profitability and a remarkable ROE make it very ...

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 21 st A...

Ovid Therapeutics press release (NASDAQ:OVID): Q4 GAAP EPS of -$0.38 misses by $0.22. Cash and cash equivalents as of December 31, 2021 was $187.8M. For further details see: Ovid Therapeutics GAAP EPS of -$0.38 misses by $0.22

Ovid executing on its strategy to build a leading epilepsy pipeline OV329 expected to enter the clinic in 2022 Organization reshaped to reduce personnel by 20% and increase operational efficiency Targeted business development continues to support the pipeline ...

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epilepsies and rare neurological disorders, today announced that management will participate virtu...

– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination Therapies for Fragile X, Other Indications – NEW YORK, N.Y. and CAMBRIDGE, United Kingdom, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics (NASDAQ:OVID) (&#...

Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapies Collaboration with Dr. Stephen Moss, founder of Tufts Laboratory for Basic and Translational Neuroscience Res...

Ovid Therapeutics (NASDAQ:OVID): Q3 GAAP EPS of -$0.17 beats by $0.03. Company ended the third quarter of 2021 with cash and cash equivalents of $201.8 million. Press Release For further details see: Ovid Therapeutics EPS beats by $0.03

Ovid is implementing its business development program which intends to secure a series of opportunities that complement and enhance its pipeline of precision and small-molecule CNS medicines A development program for soticlestat, which Ovid licensed to Takeda, has begun enrolling ...